Objective:To explore the influence of depression on heart rate variability(HRV) and short term prognosis of patients with acute myocardial infarction(AMI).Methods:120 AMI patients were evaluated with Zung's self-rating depression scale within 24 hours after admission.The patients were divided into depressive group(45 cases) and non-depressive group(75 cases) according to depressive index.Post-infarction angina pectoris,reinfarction,heart failure and ventricular fibrillation as well as cardiac death were observed during 4 weeks.HRV analysis with 24-hour holter of survivals was perfomed in 1 week after infarction.Results:The prevalence of post-infarction angina pectoris,ventricular fibrillation and cardiac death in depressive group was remarkably elevated compared with non-depressive group(40.0% vs 22.7%,20.0% vs 6.7%,17.8% vs 4.0%,respectively. P

Objective To establish a multi-parameter diagosis criteria for Myelodysplastic syndromes(MDS).Methods Eight diagnostic parameters for MDS obtained from our retrospective study were prospectively studied.From Jan.2000 to June 2004,leukemic transformations in 38 MDS patients diagnosed according to the multi-parameter criteria plus WHO criteria were dynamically followed up,and compared with that in 79 MDS cases who were diagnosed only according to WHO criteria contemporaneously and that in 123 MDS cases historially who fit in with WHO criteria.Results Eighteen of the 38 MDS patients transferred into leukemia.Among the 79 MDS patients diagnosed only according to the WHO criteria,18 transferred(P

PURPOSE: Data comparing the long-term efficacy and safety of subcutaneous immunotherapy (SCIT) using house dust mite (HDM) in children and adults with allergic rhinitis (AR) are limited. This study aimed to compare the long-term effects of HDM-SCIT in a cohort of Chinese pediatric and adult patients with AR. METHODS: A total of 124 pediatric and adult AR patients received HDM-SCIT for 3 years, with 118 patients being followed-up for 2 years. Prior to treatment (baseline), at the end of the 3-year treatment periods (third year) and 2 years after the discontinuation of treatment (fifth year), all patients were evaluated for total nasal symptom scores (TNSS), daily medication score (DMS), total combined score (TCS; symptoms [nasal + ocular] + DMS) and quality of life (QoL). Safety was assessed according to adverse events reported. RESULTS: After 3-year treatment, HDM-SCIT significantly improved symptoms and QoL scores at the end of the third and fifth years in both groups. Better improvements were observed in the third and fifth years based on baseline, in children compared to adults (TNSSΔ3: 6.66 vs. 5.41, P = 0.011; TCSΔ3: 4.30 vs. 3.83, P = 0.027 and TNSSΔ5: 6.16 vs. 4.86, P = 0.037; TCSΔ5: 4.11 vs. 3.62, P = 0.044).Shorter duration of AR history before SCIT (<10 vs. ≥10 years) resulted in better improvements at the end of the third and fifth years (TCSΔ3: 4.12 vs. 3.13, P = 0.036; TCSΔ5: 3.90 vs. 3.09, P = 0.033). HDM-SCIT was safe and comparable in both children and adults with AR. CONCLUSIONS: Children with AR may achieve better long-term efficacy of HDM-SCIT than adults with AR.
Adult* ; Asian Continental Ancestry Group ; Child ; Cohort Studies ; Humans ; Immunotherapy* ; Pyroglyphidae ; Quality of Life ; Rhinitis, Allergic* ; Treatment Outcome